Vivek Subbiah: An Honor to Deliver Two Keynote Lectures at the OncoNext Meeting / cancer, Fabio Franke, Juliana Beal, OncoDaily, Oncology, Roberto Pestana,

Vivek Subbiah: Tumor-Agnostic Therapies and the Need for Living Guidelines / ASCO, cancer, Jim Palma, OncoDaily, Oncology, Razelle Kurzrock, Thomas K. Oliver,

Vivek Subbiah: ARROW Study Final Results in RET-Positive Lung Cancer / 19th annual New York Lung Cancers Symposium, Aaron S. Mansfield, Amber Thomassen,

Vivek Subbiah: Honoring the Life, the Legacy, and the Light He Continues to Shine... / cancer, Martin Luther King, OncoDaily, Oncology, Vivek Subbiah

Vivek Subbiah: Shared Vision for Accelerating Tissue-Agnostic Drug Development at Miami Precision Oncology Symposium / Baptist health, cancer, Manmeet

Vivek Subbiah: AI-Driven Screening Opens New Era in Drug Discovery / Bowen Gao, cancer, Chuangye Yan, Haichuan Tan, Hongyi Cai, Jiaxin Tan, Jiekang Tian,

Vivek Subbiah: Rethinking Cancer of Unknown Primary in Precision Oncology Era / cancer, F. Anthony Greco, Journal of Clinical Oncology, OncoDaily, Oncology,

Great Debates Congratulates Yelena Janjigian and Vivek Subbiah on Being Named Among the Most Influential People in Oncology in 2025 / cancer, Great Debates,

Vivek Subbiah Shares a Study on Why Cancer Can Return Years Later and How to Stop It / cancer, OncoDaily, Oncology, Vivek Subbiah

10 Papers Suggested by Vivek Subbiah / Alessio Nencioni, Alexander G Bick, Ali J. Haidar, Ana Barac, Ana Guijarro, Andres Daniele, Angela Chen, Ashwin

Researchers are targeting dormant tumour cells that might explain why some cancers reappear long after successful treatment.

10 Must-Read Posts in GI Oncology This Week / cancer, cancer care, Cancer research, cancer treatment, clinical trials, Colorectal Cancer (CRC),

The rise of AI scientists, missions to explore the moons of Earth and Mars and a massive ocean-floor drill are among the developments set to shape research in 2026.

Vivek Subbiah: Tissue-Agnostic Cancer Therapies Promise to Revolutionize Oncology by Targeting Molecular Drivers / cancer, cancer treatment, Headlines,

Vivek Subbiah: Thrilled to Share My Editorial on the ROME Trial / Agnese Fabbri, Alberto Zambelli, Andrea Botticelli, Andrea DeCensi, Annamaria Pessino, Bruna

Vivek Subbiah: ONE of the Most Impactful Meetings in Rare Cancer Research / cancer, OncoDaily, Oncology, Razelle Kurzrock, Target Cancer Foundation, Think

Vivek Subbiah: ESMO 2025 - Catalyzing Novel Collaborations for Global Impact in Oncology / cancer, ESMO, ESMO 2025, OncoDaily, Oncology, Vivek Subbiah

Vivek Subbiah: Honored to Present at ESMO Annual Meeting Young Oncologists Clinical Case Discussions / cancer, ESMO Annual Meeting, ESMO25, Maximilian Kloft,

Vivek Subbiah: Precision Oncology and Modernizing Evidence Standards / cancer, OncoDaily, Oncology, Razelle Kurzrock, Vivek Subbiah

Vivek Subbiah: ESMO Presidential Dinner is Kicking Off in Berlin / cancer, ESMO, ESMO 2025, ESMO 2025 Congress, ESMO Presidential Dinner, ESMO2025, ESMO25,

Vivek Subbiah: Rethinking Cancer Drug Development Through Tumor-Agnostic Precision Medicine / cancer, ESMO, ESMO 2025, ESMO 2025 Congress, ESMO2025, ESMO25,

Vivek Subbiah: Smarter Trial Designs - How Project Optimus is Changing Early-Phase Cancer Research / American Society of Clinical Oncology, ASCO, cancer,

Vivek Subbiah: Impact of FDA Project Optimus Guidance on Early-Phase Trial Design / cancer, David Spigel, Deepak Bhamidipati, Gerald Falchook, Howard Burris,

Vivek Subbiah: Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series / cancer, International Cancer Patient Coalition,

A Spanish foundation using an artificial-intelligence tool to screen grant applications says it makes the peer-review process more efficient, but other researchers say it’s a breakdown in trust.

10 Must-Read Posts in Immuno-Oncology This Week / Alex Menzies, Alexander Van Akkooi, AndrewFurness, cancer, chemoimmunotherapy, Christian Blank, David

Vivek Subbiah: Nature Medicine Study on Molecular Profiling in Meningioma / Alexander P. Landry, Andrew Ajisebutu, cancer, Chloe Gui, Farshad Nassiri, Gelareh

Vivek Subbiah: Rare Cancers Deserve Breakthroughs Too / American Society of Clinical Oncology, ASCO, cancer, Conquer Cancer, Conquer Cancer the ASCO

Top Articles Suggested by Vivek Subbiah / cancer, Nature, NEJM, OncoDaily, Oncology, Vivek Subbiah

Interview with Jiyoung Ahn, PhD, author of Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. Hosted by Vivek Subbiah, MD.

Vivek Subbiah: Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center / cancer, Fred Hutch Cancer Center, OncoDaily,

Top 5 Articles of the Week Suggested by Vivek Subbiah / cancer, Cancer Discovery, Nature, OncoDaily, Oncology, Sarah Cannon Research Institute, Vivek Subbiah

Adagrasib demonstrated a statistically significant improvement in progression-free survival over docetaxel in patients with previously treated KRASG12C-mutated NSCLC, without new safety signals.

Within hypermutated colorectal cancer, younger patients exhibited a higher mutational burden than older patients. Our study reveals an abnormal accumulation of distinct somatic mutations in hypermutat...

We did not find significant evidence of an overall survival benefit of adding metformin to standard of care in the overall population of patients with metastatic hormone-sensitive prostate cancer. The...

Vivek Subbiah: We Don’t Just Write What We Know, We Write to Discover What We Could Know / cancer, Nature Reviews Bioengineering, OncoDaily, Oncology, Vivek

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Happy 4th everyone! Delighted to share with the our comment just published in t...

Vivek Subbiah: How Clinical Trials Offer Hope for Those Facing Limited Options / cancer, OncoDaily, Oncology, Sarah Cannon Research Institute, Sarcoma

Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting molecular drivers. Sledge et al.’s study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications. Despite ...